Aptose Announces Auditor Not Standing for Re-Appointment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2025
0mins
Source: Newsfilter
KPMG's Departure: Aptose Biosciences announced that KPMG LLP will not be re-appointed as its independent auditor for the 2025 annual audit, although they will continue to review quarterly financial results until mid-2025. The decision was made without the Company's consent or involvement from its Board of Directors.
Company Overview: Aptose is a clinical-stage biotechnology firm focused on developing precision oncology treatments, particularly for acute myeloid leukemia (AML), with its lead compound tuspetinib (TUS) being developed as a frontline therapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
